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Abstract
There isan increasing interest inusing microRNAs (miRNA) as biomarkers inautoimmune diseases. They areeasilyaccessible in
many bodyfluidsbutit is controversial if they arecirculating freely or areencapsulatedin microvesicles,particularly exosomes.
Weinvestigated if the majorityof miRNas inserum andsalivaarefree-circulating or concentratedinexosomes. Exosomeswere
isolated by ultracentrifugation from fresh and frozen human serum and saliva. The amount of selected miRNAs extracted from
the exosomal pellet and the exosome-depleted serum and saliva was compared by quantitative RT-PCR. Some miRNAs tested
are ubiquitously expressed, others were previously reported as biomarkers. We included miRNAs previously reported to be
free circulating and some thought to be exosome specific. The purity of exosome fraction was confirmed by
electronmicroscopy and western blot. The concentration of miRNAs was consistently higher in the exosome pellet compared
to the exosome-depleted supernatant. We obtained the same results using an equal volume or equal amount of total RNA as
input of the RT-qPCR. The concentration of miRNA in whole, unfractionated serum, was between the exosomal pellet and the
exosome-depleted supernatant. Selected miRNAs, which were detectable in exosomes, were undetectable in whole serum
and the exosome-depleted supernantant. Exosome isolation improves the sensitivity of miRNA amplification from human
biologic fluids. Exosomal miRNA should be the starting point for early biomarker studies to reduce the probability of false
negative results involving low abundance miRNAs that may be missed by using unfractionated serum or saliva.
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Introduction
Many of the systemic autoimmune diseases have heterogeneous
clinical presentations making accurate diagnosis and monitoring of
clinical activity difficult. Therefore, there is a need to identify and
validate non-invasive biomarkers, which can be used to improve
the accuracy of diagnosis, predict prognosis and to monitor disease
progression and response to therapy.
MicroRNAs (miRNAs) are small regulatory non-coding RNAs
with important roles in a variety of physiological and pathological
processes. Among others they are instrumental in regulating
immune development, normal immune function and autoimmu-
nity. MiRNAs can be readily isolated from fresh or fixed tissues
and body fluids. Their expression patterns reflect the pathophys-
iological status of a tissue [1] and have been shown to be specific
for particular disease states. Additionally, miRNAs are more stable
than mRNAs and thus less prone to minor differences in sample
processing. Together these characteristics make them excellent
biomarker candidates. Easily accessible body fluids such as blood
derivatives and saliva or urine would provide an ideal source for
miRNA biomarkers. It was shown previously that miRNA
signatures from plasma, serum and whole blood were not
significantly different [2,3] and it was hypothesized that miRNAs
were encapsulated in separate structures.
Exosomes are small microvesicles, about 30–100 nm in size [4].
They are secreted by a variety of cell types such as epithelial cells,
B- and T-lymphocytes [5], mast cells [6], dendritic cells [6], and
neurons [7] and carry proteins and nucleic acids. MiRNA
signatures from both unfractionated whole serum, urine, saliva,
cerebrospinal fluid [8] and from exosomes [9] showed promise as
diagnostic biomarkers, but there is no consensus about the relative
contribution of exosomal miRNAs to whole serum microRNAs.
Determining this would have important practical implications on
miRNA biomarker studies as well as studies exploring the biologic
function of circulating miRNAs.
The goal ofthisstudywastodetermine ifmiRNAs found inserum
and salivaareprimarilyinexosomesandwhetherthereisanybenefit
of using exosomes over unfractionated biologic fluids in biomarker
studies. In contrast to two recent papers [10,11] which claimed that
the majority of miRNAs found in plasma and serum is present
primarily outside exosomes here we demonstrate that miRNAs in
serum and saliva exist primarily inside exosomes and that using
exosomal fraction increases the sensitivity of miRNA detection.
Results
Exosome isolation
We first optimized an ultracentrifugation protocol to isolate
exosomes from small amounts (,1 mL) of fresh and frozen human
serum and saliva. Electron microscopic analysis of the pellet
showed spherical structures with a size varying between 50–
110 nm (Fig. 1a), consistent with previously reported character-
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are exosomes by performing Western blot analysis on lysates of the
ultracentrifugation pellets using antibodies against two commonly
used exosomal markers, the tetraspanin molecule CD63, and
TSG101 [13,14] (Fig. 1b).
Majority of miRNAs are within exosomes in human serum
and human saliva samples
To determine if the miRNA in serum or saliva is contained in
exosomes or is circulating freely, we extracted the RNA from the
exosomes in the pellet and from the exosome-depleted supernatant
from both serum and saliva. The optimized exosome isolation
method allowed us to start from small volumes of samples (300 ml-
1 ml) and to use the whole exosomal pellet and the entire volume
of the supernatant for RNA isolation. The RNA isolated from
both sources was dissolved in a volume of 25 mL. The amount of
selected miRNAs was compared by determining their threshold
cycle (Ct) by real-time quantitative (RT-qPCR). The Ct is defined
as the cycle number at which the fluorescence emission exceeds a
fixed threshold. A Ct of 35 was considered the lower level of
detection. Undetectable miRNAs were given a Ct value of 40. The
miRNAs tested in serum and saliva samples are shown in Table 1.
These miRNAs were selected because they are either ubiquitously
expressed or have been reported as biomarkers (Table 1). The
relative concentration of these microRNAs was determined by
calculating the difference of Ct values between the exosome
samples and the exosome-depleted supernatant. A 1-unit differ-
ence in the Ct value between the miRNAs isolated from the
exosomal pellet or supernatant represents a 2-fold difference in the
amount of input miRNA.
To explore the effect of various normalization approaches we
performed two sets of RT-qPCRs on miRNAs derived from sera
normalizing for input RNA or original volume. First we
retrotranscribed 10 ng of RNA for each sample. Using the same
amount of RNA avoids artifacts that may result from including
different amounts in the qRT-PCR reaction. This is particularly
important for RNAs present at low copy numbers. However, this
normalization may lead to a disproportionate representation of the
original volumes these RNAs were derived from. In fact, since the
concentration of RNA derived from the supernatant was higher
than the exosomal RNA, equal amounts of exosomal RNA
represents a larger volume of serum than the RNA form the
supernatant. To address this, we repeated these experiments using
the same volume of RNA, which represents the same volume of
serum for both the pellet and the supernatant. As shown in
Figure 2a, the concentration of the miRNAs was consistently
higher in the exosomes regardless of the normalization. The mean
in the pellet is at least 6 fold (2.2 cycles) higher than in the
supernatant for all the miRNAs tested. The difference ranges from
6–128 folds (2.2–12.5 cycles). To put it differently, 83% to more
than 99% of miRNAs is detected in the exosomal fraction. In fact
many miRNAs were under the lower range of reliable detection
(Ct.35) in the exosome-depleted supernatant. We obtained
similar results when we used the same volume rather than the
same amount of miRNA for the RT-qPCR (Figure 2b). Together
these data show that the majority of miRNAs are contained in
exosomes and there is no substantial difference whether we use
equal amounts or volume of input RNA. The rest of the data
presented in this paper show the results of experiments using equal
amounts of RNA.
Figure 1. Confirmation that the ultracentrifugation pellet contains exosomes. a Electron microscopy of the ultracentrifugation pellet from
serum shows the characteristic spherical shape and size (50–100 nm) of exosomes b. Western blot shows strong staining of the ultracentrifugation
pellet with the exosomal membrane markers anti cd63 and TSG101.
doi:10.1371/journal.pone.0030679.g001
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miRNA obtained using the same amount of RNA (2c) or the same
volume of sample (2d). The Ct value for the majority of miRNAs
was above 35 cycles, which is considered as the threshold for
reliable detection of miRNAs, showing that most miRNAs tested
are either absent or present at a very low level outside exosomes
but can be reliably detected in isolated exosomes.
To evaluate if this observation is applicable to other biologic
fluids we also tested miRNA concentration in salivary exosomes
and exosome-depleted supernatants of saliva. The miRNAs tested
in the saliva samples (Table 1) were previously shown to be present
in saliva or salivary glands (Fig. 3a). Overall, the concentration of
these miRNAs was lower in salivary exosomes compared to the
ones tested in the serum. In the saliva samples, 3/4 of the miRNAs
tested were undetectable (Ct.40 cycles). The one miRNA that
was detectable in the exosome-depleted supernatant was also
above the recommended threshold for detection and was 32-fold
(5 cycles) more concentrated in exosomes.
MiRNA in whole serum
Next we addressed the question if there was a potential benefit
in using exosomal miRNA over whole serum to detect circulating
miRNAs. To answer this question, we processed half the samples
as previously described (exosome isolation and RNA extraction)
whereas from the other half we extracted RNA directly, skipping
the exosome isolation step (whole serum).
As shown in Figure 3b the Ct value for the whole serum samples
was consistently lower (by at least 2 cycles) than the supernatant
and at least 1.5 cycles higher than the exosome pellet samples.
Discussion
Together these data demonstrate that the exosome fraction of
serum and saliva is highly enriched in miRNAs, and that the
majority of this class of RNA is not freely circulating in human
biologic fluids but is enclosed in microvesicles, primarily exosomes.
The finding that miRNAs are primarily in exosomes was
consistent for all miRNAs tested, for both fresh and frozen serum
(data not shown), for various biologic fluids (serum and saliva) and
across all healthy individuals tested and the patient with systemic
lupus erythematosus. This finding is in apparent contrast with two
recent publications, which found that miRNAs are predominantly
exosome-free in cell culture media [10], and bound to Argonaut-2
protein in plasma and serum [11]. The reason for this difference is
unclear but may, at least in part, be due to minor differences in
isolating exosomes or differences between plasma and serum. In
fact Arroyo et al showed that in contrast to plasma, in serum
miRNA was more commonly found in exosomes than circulating
freely. To address this discrepancy we tested some of the miRNAs,
which were studied by Arroyo et al (let-7a, miR-92a, miR142-3p).
In contrast to their study, which found that some are primarily in
exosomes whereas others are circulating freely, we found that the
all of these miRNAs are primarily in exosomes. The reason for this
difference may be due to low grade lysis of exosomes during the
exosome isolation process.
Comparing miRNA detection from whole serum and isolated
exosomes showed that exosome isolation improves the sensitivity
of miRNA amplification from human biologic fluids. This
difference was relatively small for some miRNAs but for one
(miR107) using exosomal miRNA substantially increased the
sensitivity of detection. We believe that the extra effort required for
exosomes isolation is justified for many applications. Exosomal
miRNA should be the starting point for early biomarker studies to
reduce the probability of false negative results involving low
abundance miRNAs that may be missed by using unfractionated
serum or saliva. Once potential biomarkers are identified in
exosomes, methods can be optimized to detect these specific




The study was approved by the Institutional Review Boards of
the National Institute of Diabetes Digestive and Kidney Diseases
and the National Institutes of Arthritis and Musculoskeletal and
Skin Diseases and the National Institute of Dental and
Craniofacial Research. All subjects have signed a written informed
consent. Serum was isolated from 6 healthy volunteers and 1
patient with systemic lupus erythematosus. Briefly, 10 ml of blood
was collected in a serum separator tube and processed within an
hour. Separation of the serum was accomplished by centrifugation
at 8006 g for 10 minutes at room temperature. The serum
obtained was further processed for exosome isolation. Saliva
samples: saliva was collected in a sterile tube and directly
processed for the exosome isolation as described in the following
paragraph.
Exosome isolation
Fluid samples were centrifuged at 15006g for 10 minutes. The
collected supernatant was centrifuged again at 17,0006 g for
15 minutes, and the supernatant was spun again in an ultracen-
Table 1. List of miRNAs tested in serum and saliva samples.
Serum miRNA Previously associated with or described as Saliva miRNA Previously associated with or described as
let-7a Exosomal miRNA
(11) miR-22 Ubiquitous
miR-92a Free circulating miRNA
(11) miR-202 Ubiquitous
miR142-3p Exosomal miRNA
(11) miR-203 Colorectal cancer




miR-574 Mononuclear infiltrates in SS
miR-768 Mononuclear infiltrates in SS
doi:10.1371/journal.pone.0030679.t001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e30679Figure 2. Serum miRNAs are predominantly in exosomes. The relative expression of microRNAs extracted from exosome-depleted
supernatant or exosomes was expressed as the difference in threshold cycle number between the exosome depleted supernatant and the exosome
pellet (DCt: Ct supernatant – Ct exosome pellet). A 1 unit difference in DCT represents a two-fold difference in the amount of input miR. Positive
numbers show higher concentrations in the exosomes whereas negative numbers indicate higher concentrations in the exosome-depleted
supernatant. The absolute difference between the two can be calculated as 2
DCT. The RNA included in the qPCR reaction was normalized to either
equal amount (a) or equal volume (b) of RNA. Panels (c) and (d) show the absolute differences in microRNA levels amplified from serum exosome
pellet (#) and exosome-depleted supernatant (%).
doi:10.1371/journal.pone.0030679.g002
Figure 3. Salivary miRNAs are predominantly in exosomes. (a) Absolute differences in microRNA levels amplified from saliva exosome pellet
(#) and exosome-depleted supernatant (%). 1 unit increase in CT represent a two-fold lower amount of miRNA. miRNAs requiring 35 cycles or more
are considered undetectable. (b) Graph showing the average of three samples in microRNA levels amplified from serum exosome pellet (#) and
exosome-depleted supernatant (%) and whole serum (n). Ct value for the whole serum samples was consistently lower (by at least 2 cycles) than the
supernatant and at least 1.5 cycles higher than the exosome pellet samples.
doi:10.1371/journal.pone.0030679.g003
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4uC. The pellet containing exosomes and the exosome-depleted
supernatant were then processed to extract RNA.
RNA Extraction and Reverse Transcription
RNA was extracted from the pellet and from the exosome-
depleted supernatant using the TRIZOL reagent (Invitrogen,
Carlsbad, CA) according to the protocol provided by the
manufacturer. Briefly, 1.0 ml TRIZOL reagent and 200 ml
chloroform were added to the sample and the mixture was
vortexed for 15 s and stood at 25uC for 3 minutes. After
centrifugation at 120006g for 15 minutes at 4uC, the supernatant
was transferred to a fresh tube and 500 ml isopropanol was added.
After incubation at 220uC for 20 minutes, the mixture was
centrifuged at 120006 g for 10 minutes at 4uC to remove the
supernatant and the RNA pellet was washed with 75% ethanol.
After removal of ethanol by centrifugation at 75006 g for
5 minutes at 4uC, RNA was air-dried for 5 minutes and then
dissolved in 25 ml RNase-free water. The purity of isolated RNA
was determined by OD260/280 using a Nanodrop ND-1000
(Thermo Scientific, Worcester, MA). Each RNA sample was
polyadenylated and reversely transcribed to cDNA using the
TaqManH MicroRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). Single-stranded cDNA was synthe-
sized from 10 ng of total RNA (normalization by amount) or from
1 ml of the RNA volume (normalization by volume) using specific
miRNA primers (TaqMan MicroRNA Assay, PN 4427975,
Applied Biosystems).
miRNA quantification
Two ml of cDNA was used as a template in a 15 ml PCR
reaction. PCR products were amplified using specific primers
(TaqMan MicroRNA Assay) and the TaqMan Universal PCR
Master Mix (PN 4324018, Applied Biosystems), and detected using
StepONE plus Real time PCR system (Applied Biosystems). PCR
reactions for each sample were run in triplicate, including blank
controls without cDNA. The following TaqMan MicroRNA
Assays used in this study were obtained from Applied Biosystems
and used miRNA detection: hsa-let-7a (000377), hsa-miR-92a
(000431), hsa-miR-142-3p (000464) miR101 (000438), miR107
(000443), miR122 (000445), miR574 (002349), miR16 (000391),
miR678 (000449) for serum and miR203 (000507), miR22
(000398), miR202 (001012), and miR1273d (000437) for saliva.
Western blot immunoblotting
Proteins were extracted from the ultracentrifugation pellets and
separated on a polyacrylamide gel before transfer to a PVDF
membrane. The blotting membrane was blocked with bovine
serum albumin and incubated with CD63 antibody (Abcam,
Cambridge, UK) and with TSG101 (Abcam, Cambridge UK)
followed by incubation with horseradish peroxidase-coupled
secondary antibody (Cell Signaling Technology, Inc. Danvers,
MA). The proteins were detected using enhanced chemilumines-
cence (Thermo Scientific, Rockford, USA).
Acknowledgments
We would like to thank Lolita Bebris, RN and Tammy Yokum, RN for her
help with conducting the clinical protocols and collection of samples and
Margaret Grisius, DDS for their help in collecting samples.
Author Contributions
Conceived and designed the experiments: AG IA GGI. Performed the
experiments: AG. Analyzed the data: AG MT. Contributed reagents/
materials/analysis tools: IA GGI. Wrote the paper: AG GGI.
References
1. Alevizos I, Illei GG (2010) MicroRNAs as biomarkers in rheumatic diseases. Nat
Rev Rheumatol 6: 391–8.
2. Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating
microRNA biomarkers in plasma and serum using quantitative reverse
transcription-PCR (qRT-PCR). Methods 50: 298–301.
3. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer detection. Proc
Natl Acad Sci U S A 105: 10513–10518.
4. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated
platelets release two types of membrane vesicles: microvesicles by surface
shedding and exosomes derived from exocytosis of multivesicular bodies and
alpha-granules. Blood 94: 3791–3799.
5. McLellan AD (2009) Exosome release by primary B cells. Crit Rev Immunol
29(3): 203–17.
6. Admyre C, Telemo E, Almqvist N, Lo ¨tvall J, Lahesmaa R, et al. (2008)
Exosomes - nanovesicles with possible roles in allergic inflammation. Allergy
63(4): 404–8.
7. Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, et al. (2011)
Release of exosomes from differentiated neurons and its regulation by synaptic
glutamatergic activity. Mol Cell Neurosci 46(2): 409–18.
8. Tzimagiorgis G, Michailidou EZ, Kritis A, Markopoulos AK, Kouidou S (2011)
Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer
Epidemiol 35(6): 580–9.
9. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, et al. (2010) Exosomes
from human saliva as a source of microRNA biomarkers. Oral Dis 16(1): 34–8.
10. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of
extracellular circulating microRNA. Nucleic Acids Res 39(16): 7223–33.
11. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. (2011)
Argonaute2 complexes carry a population of circulating microRNAs indepen-
dent of vesicles in human plasma. Proc Natl Acad Sci U S A 22; 108(12):
5003–8.
12. Silverman JM, Reiner NE (2011) Exosomes and other microvesicles in infection
biology: organelles with unanticipated phenotypes. Cell Microbiol 13(1): 1–9.
13. The ´ry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis
and function. Nat Rev Immunol 2: 569–579.
14. Lakkaraju A, Rodriguez-Boulan E (2008) Itinerant exosomes: emerging roles in
cell and tissue polarity. Trends Cell Biol 18: 199–209.
Circulating MicroRNA in Body Fluids Is in Exosomes
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e30679